FDA Rejects Approval Of Change To Nuvo Anesthetic Cream
The agency sent a so-called complete response letter to the Galderma Pharma SA unit that holds the worldwide marketing rights to the product, known as Pliaglis, saying it would not approve a supplemental new drug application unless it was provided with more information about the product, according to Nuvo.
Nuvo did not specify what issues the letter cited, saying only...
Already a subscriber? Click here to login